1] Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA [2] Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA.
Division of Genomic Medicine, National Human Genome Research Institute, Bethesda, Maryland 20892, USA.
Nature. 2014 Apr 24;508(7497):469-76. doi: 10.1038/nature13127.
The discovery of rare genetic variants is accelerating, and clear guidelines for distinguishing disease-causing sequence variants from the many potentially functional variants present in any human genome are urgently needed. Without rigorous standards we risk an acceleration of false-positive reports of causality, which would impede the translation of genomic research findings into the clinical diagnostic setting and hinder biological understanding of disease. Here we discuss the key challenges of assessing sequence variants in human disease, integrating both gene-level and variant-level support for causality. We propose guidelines for summarizing confidence in variant pathogenicity and highlight several areas that require further resource development.
罕见遗传变异的发现正在加速,因此迫切需要明确的指导方针,以区分致病序列变异与任何人类基因组中存在的许多潜在功能变异。如果没有严格的标准,我们可能会加速因果关系的假阳性报告,从而阻碍将基因组研究发现转化为临床诊断环境,并阻碍对疾病的生物学理解。在这里,我们讨论了评估人类疾病中序列变异的关键挑战,将基因水平和变异水平对因果关系的支持都整合在一起。我们提出了总结变异致病性置信度的指南,并强调了几个需要进一步资源开发的领域。